IL127559A0 - Compounds and methods for providing pharmacologically active preparations and uses thereof - Google Patents
Compounds and methods for providing pharmacologically active preparations and uses thereofInfo
- Publication number
- IL127559A0 IL127559A0 IL12755997A IL12755997A IL127559A0 IL 127559 A0 IL127559 A0 IL 127559A0 IL 12755997 A IL12755997 A IL 12755997A IL 12755997 A IL12755997 A IL 12755997A IL 127559 A0 IL127559 A0 IL 127559A0
- Authority
- IL
- Israel
- Prior art keywords
- compounds
- methods
- pharmacologically active
- active preparations
- providing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1608896P | 1996-06-20 | 1996-06-20 | |
PCT/US1997/010643 WO1997048694A1 (fr) | 1996-06-20 | 1997-06-20 | Composes et procedes d'obtention de preparations pharmacologiquement actives et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
IL127559A0 true IL127559A0 (en) | 1999-10-28 |
Family
ID=21775328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12755997A IL127559A0 (en) | 1996-06-20 | 1997-06-20 | Compounds and methods for providing pharmacologically active preparations and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US6720344B2 (fr) |
EP (1) | EP0912549A4 (fr) |
JP (1) | JP2000514048A (fr) |
KR (1) | KR20000022040A (fr) |
CN (1) | CN1226245A (fr) |
AU (1) | AU727708B2 (fr) |
BR (1) | BR9711805A (fr) |
CA (1) | CA2258822A1 (fr) |
HU (1) | HUP9904567A3 (fr) |
IL (1) | IL127559A0 (fr) |
NO (1) | NO985975L (fr) |
PL (1) | PL330814A1 (fr) |
WO (1) | WO1997048694A1 (fr) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0973513A4 (fr) * | 1996-10-23 | 2003-03-19 | Zymogenetics Inc | Compositions et methodes pour traiter les etats associes a un deficit osseux |
US6376476B1 (en) | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
EA009370B1 (ru) | 1997-05-14 | 2007-12-28 | Атеродженикс, Инк. | Соединение и фармацевтическая композиция для ингибирования экспрессии vcam-1 |
US6670398B2 (en) | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
CA2309882A1 (fr) * | 1997-12-22 | 1999-07-01 | Pharmacia & Upjohn Company | 4-hydroxyquinoline-3-carboxamides et hydrazides utilises comme agents antiviraux |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6780883B2 (en) | 1998-11-05 | 2004-08-24 | Warner-Lambert Company | Amide inhibitors of microsomal triglyceride transfer protein |
DE60140491D1 (de) | 2000-08-29 | 2009-12-24 | Biocon Ltd | Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts |
JP4341949B2 (ja) | 2000-09-01 | 2009-10-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | アザ複素環式誘導体およびその治療的使用 |
EP1317442B1 (fr) | 2000-09-11 | 2005-11-16 | Chiron Corporation | Derives de quinolinone comme inhibiteurs de tyrosine kinase |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US7642278B2 (en) | 2001-07-03 | 2010-01-05 | Novartis Vaccines And Diagnostics, Inc. | Indazole benzimidazole compounds |
US8048924B2 (en) * | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
JP4613130B2 (ja) | 2002-08-23 | 2011-01-12 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | ベンゾイミダゾールキノリノンおよびそれらの使用 |
JP2006511616A (ja) | 2002-11-13 | 2006-04-06 | カイロン コーポレイション | 癌の処置方法およびその関連方法 |
US20040192728A1 (en) | 2003-02-03 | 2004-09-30 | Ellen Codd | Quinoline-derived amide modulators of vanilloid VR1 receptor |
TW200526631A (en) | 2003-10-07 | 2005-08-16 | Renovis Inc | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
KR20060111520A (ko) | 2003-11-07 | 2006-10-27 | 카이론 코포레이션 | Fgfr3의 억제 및 다발성 골수종의 치료 |
CA2556872C (fr) | 2004-02-20 | 2015-05-12 | Chiron Corporation | Modulation de processus inflammatoires et metastiques |
ES2656017T3 (es) | 2004-06-24 | 2018-02-22 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
DK1773767T3 (en) | 2004-07-07 | 2016-03-21 | Biocon Ltd | Synthesis of azo bound in immune regulatory relations |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
EP1845990B1 (fr) | 2005-01-27 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Traitement de tumeurs metastatiques |
US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
ES2376347T3 (es) | 2005-05-17 | 2012-03-13 | Novartis Ag | Métodos para sintetizar compuestos heteroc�?clicos. |
AU2006320591B2 (en) | 2005-11-29 | 2010-06-03 | Novartis Ag | Formulations of quinolinones |
WO2007075901A2 (fr) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Promedicaments de modulateurs de transporteurs abc |
DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
GB2453058A (en) | 2006-04-04 | 2009-03-25 | Univ California | Kinase antagonists |
CA2676984C (fr) | 2007-02-01 | 2015-03-17 | Resverlogix Corp. | Composes destines a la prevention et au traitement de maladies cardiovasculaires |
WO2008118948A1 (fr) | 2007-03-26 | 2008-10-02 | Atherogenics, Inc. | Procédés et compositions de dérivés de probucol pour le traitement du diabète |
US20110160232A1 (en) * | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
WO2009114870A2 (fr) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Inhibiteurs de kinases, et procédés d’utilisation associés |
WO2009114874A2 (fr) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés |
US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
EP2313414B1 (fr) * | 2008-07-08 | 2015-11-04 | Intellikine, LLC | Inhibiteurs de kinases et procédés d'utilisation |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
CA2738429C (fr) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Inhibiteurs heterocycliques de kinases |
DK2358720T3 (en) | 2008-10-16 | 2016-06-06 | Univ California | Heteroarylkinaseinhibitorer fused-ring |
BRPI0919930A2 (pt) | 2008-10-23 | 2016-02-16 | Vertex Pharma | moduladores de regulador de condutância transmembrana de fibrose cística |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
ES2542835T3 (es) | 2009-01-08 | 2015-08-12 | Resverlogix Corporation | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
JP5795304B2 (ja) | 2009-03-18 | 2015-10-14 | レスバーロジックス コーポレイション | 新規抗炎症剤 |
EP3330255B1 (fr) | 2009-03-20 | 2020-12-09 | Vertex Pharmaceuticals Incorporated | Procédé de fabrication de modulateurs de régulateur de conductance transmembranaire de la fibrose kystique |
KR101892987B1 (ko) | 2009-04-22 | 2018-08-30 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
ES2593256T3 (es) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Compuestos químicos, composiciones y métodos para las modulaciones de cinasas |
WO2011153531A1 (fr) | 2010-06-04 | 2011-12-08 | University Of South Florida | Procédé de traitement de dysplasies squelettiques mettant en œuvre un vasodilatateur |
EP2624695B1 (fr) | 2010-10-08 | 2015-09-23 | Nivalis Therapeutics, Inc. | Nouveaux composés quinoléine substitués en tant qu'inhibiteurs de s-nitrosoglutathione réductase |
EP2637669A4 (fr) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Composés hétérocycliques et utilisations de ceux-ci |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
JP5990187B2 (ja) | 2010-12-16 | 2016-09-07 | ニヴァリス・セラピューティクス・インコーポレーテッド | S−ニトロソグルタチオン還元酵素阻害薬としての新規な置換二環芳香族化合物 |
ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
TWI565709B (zh) | 2011-07-19 | 2017-01-11 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
WO2013032591A1 (fr) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Composés hétérocycliques et leurs utilisations |
MX370814B (es) | 2011-09-02 | 2020-01-08 | Univ California | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. |
CA2851996C (fr) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Compositions pharmaceutiques pour des quinazolinones substituees |
AU2013226076B2 (en) | 2012-02-27 | 2017-11-16 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
CN104995192A (zh) | 2012-09-26 | 2015-10-21 | 加利福尼亚大学董事会 | Ire1的调节 |
WO2014080291A2 (fr) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Dérivés biaryle servant d'inhibiteurs de bromodomaines |
WO2014080290A2 (fr) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Amines cycliques servant d'inhibiteurs de bromodomaines |
EP2935253B1 (fr) | 2012-12-21 | 2018-08-01 | Zenith Epigenetics Ltd. | Nouveaux composés hétérocycliques en tant qu'inhibiteurs de bromodomaine |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
ES2900806T3 (es) | 2013-10-04 | 2022-03-18 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos |
WO2015051241A1 (fr) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | Pi3k−ガンマ媒介障害の治療で使用するための複素環式化合物 |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016025496A1 (fr) * | 2014-08-11 | 2016-02-18 | Lacerta Technologies Inc. | Facteur plaquettaire 4 destiné à être utilisé dans le traitement de maladies osseuses |
CN107073066B (zh) | 2014-09-11 | 2021-09-17 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
JP6746569B2 (ja) | 2014-10-07 | 2020-08-26 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 |
CA2977308A1 (fr) | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions et procedes therapeutiques pour le traitement de maladies associees au complement |
US10399946B2 (en) | 2015-09-10 | 2019-09-03 | Laurel Therapeutics Ltd. | Solid forms of an S-Nitrosoglutathione reductase inhibitor |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
WO2017161116A1 (fr) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3474856B1 (fr) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Therapies combinées |
IL312291A (en) | 2018-05-01 | 2024-06-01 | Revolution Medicines Inc | C-26-linked rapamycin analogs as MTOR inhibitors |
LT3788049T (lt) | 2018-05-01 | 2023-07-25 | Revolution Medicines, Inc. | Rapamicino analogai, sujungti su c40-, c28- ir c32-, kaip mtor inhibitoriai |
CN114105902B (zh) * | 2018-12-28 | 2023-11-03 | 中山大学 | 噻唑苯甲酰胺衍生物及其在制备抗骨质疏松药物中的应用 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1148908A (en) * | 1965-04-19 | 1969-04-16 | Sumitomo Chemical Co | Indole derivatives and processes for making them |
LU63457A1 (fr) * | 1970-07-06 | 1971-11-12 | ||
US4054574A (en) | 1976-05-24 | 1977-10-18 | Velsicol Chemical Corporation | 1-Benzothiazolyl-5-amino-imidazolidinones |
DE2943125A1 (de) * | 1979-10-25 | 1981-05-14 | Troponwerke GmbH & Co KG, 5000 Köln | Verfahren zur herstellung von 1-(4-chlorbenzoyl)-5-methoxy-2-methyl-3-indol acetoxyessigsaeure |
FR2509728A1 (fr) * | 1981-07-17 | 1983-01-21 | Roussel Uclaf | Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
US4560549A (en) * | 1983-08-24 | 1985-12-24 | Lever Brothers Company | Method of relieving pain and inflammatory conditions employing substituted salicylamides |
US4607053A (en) * | 1984-05-17 | 1986-08-19 | E. R. Squibb & Sons, Inc. | Arylhydroxamates useful as antiallergy agents |
FR2566407B1 (fr) * | 1984-06-25 | 1986-09-26 | Roussel Uclaf | Nouveaux derives de l'isoxazoloquinoleine, procede de preparation, application a titre de medicaments, et compositions les renfermant |
JPS61225168A (ja) * | 1985-03-30 | 1986-10-06 | Nippon Tokushu Noyaku Seizo Kk | 新規ベンズアミド、その製法及び殺虫剤 |
FR2583404B1 (fr) * | 1985-06-17 | 1990-04-13 | Pechiney Uranium | Procede de separation, par precipitation, du molybdene contenu dans des solutions de nitrate d'uranyle. |
JPS62114976A (ja) * | 1985-11-13 | 1987-05-26 | Nippon Tokushu Noyaku Seizo Kk | 新規ベンズイミデ−ト類及び殺虫殺ダニ剤 |
EP0261459A3 (fr) * | 1986-09-09 | 1988-05-11 | Nihon Tokushu Noyaku Seizo K.K. | N-benzothiazolylamides |
US5154931A (en) | 1986-10-22 | 1992-10-13 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Growth-stimulating material derived from porcine bone therefor and a manufacturing process |
FI91859C (fi) | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
WO1989003829A1 (fr) * | 1987-10-30 | 1989-05-05 | Aktiebolaget Hässle | Omeprazole permettant le traitement de maladies relatives a la perte osseuse |
JPH01203325A (ja) * | 1988-02-08 | 1989-08-16 | Takeda Chem Ind Ltd | 骨粗鬆症予防治療剤 |
US4874864A (en) * | 1988-05-24 | 1989-10-17 | Pfizer Inc. | Benzamide protease inhibitors |
US4970318A (en) | 1988-05-24 | 1990-11-13 | Pfizer Inc. | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
CA2015473C (fr) | 1989-04-28 | 1998-04-14 | Iwao Kinoshita | Derives de triphenylmethane |
SE8902076D0 (sv) * | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
WO1990015801A1 (fr) | 1989-06-22 | 1990-12-27 | Pfizer Inc. | Sulfamides substitues et composes apparentes dans le traitement de l'asthme, de l'arthrite et des maladies apparentees |
JPH03130216A (ja) * | 1989-07-21 | 1991-06-04 | Takeda Chem Ind Ltd | 骨吸収抑制剤 |
JPH03181465A (ja) * | 1989-12-11 | 1991-08-07 | Takeda Chem Ind Ltd | キノリン誘導体 |
JPH0717589B2 (ja) | 1990-01-22 | 1995-03-01 | ファイザー製薬株式会社 | 新規1,3―ジカルボニル化合物およびその組成物 |
DE4014171A1 (de) | 1990-05-03 | 1991-11-07 | Basf Ag | Cyanochinolinverbindungen |
DE69211723T2 (de) * | 1991-02-15 | 1996-10-31 | Takeda Chemical Industries Ltd | Mit einem Zellwachstumsfaktor bewirkte Anregung von Wachstum im Knocheninneren |
US5525695A (en) | 1991-10-15 | 1996-06-11 | The Dow Chemical Company | Elastic linear interpolymers |
US6277537B1 (en) | 1991-12-06 | 2001-08-21 | Eastman Kodak Company | Dye diffusion image separation systems with thermal solvents |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
WO1994003432A1 (fr) * | 1992-08-07 | 1994-02-17 | The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services | Derives de 2-carboxylate de naphtyle polyhydroxyle et de 3-carboxylate de quinolyle et d'isoquinolyle utilises comme inhibiteurs de la proteine-tyrosine-kinase |
US5322847A (en) | 1992-11-05 | 1994-06-21 | Pfizer Inc. | Azabenzimidazoles in the treatment of asthma, arthritis and related diseases |
US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
KR960701648A (ko) * | 1993-03-29 | 1996-03-28 | 마크 제이. 머레이 | Pdgf와 비타민 d를 함유하는 조골세포 성장 자극 조성물(oesteoblast growth stimulating compostion containing pdgf and vitamind) |
GB9307014D0 (en) | 1993-04-02 | 1993-05-26 | Laporte Plc | Protecting group for use in oligodeoxyribonucleotide synthesis |
US5468587A (en) | 1993-06-08 | 1995-11-21 | Eastman Kodak Company | Hydrogen bond accepting groups on thermal solvents for image separation systems |
US5430144A (en) * | 1993-07-26 | 1995-07-04 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
US5545735A (en) * | 1993-10-04 | 1996-08-13 | Merck & Co., Inc. | Benzo-Fused Lactams promote release of growth hormone |
US5389646A (en) * | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
US5478847A (en) * | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
US5637598A (en) * | 1994-11-18 | 1997-06-10 | Eli Lilly And Company | Methods of inhibiting bone loss |
US5665890A (en) | 1995-03-14 | 1997-09-09 | President And Fellows Of Harvard College | Stereoselective ring opening reactions |
US5635197A (en) * | 1995-03-21 | 1997-06-03 | Eli Lilly And Company | Treatment and prevention of prostatic cancer metastasis |
US5550134A (en) * | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
EP0839155B1 (fr) | 1995-07-17 | 2004-10-13 | Medivir UK Ltd | INHIBITEURS DE LA CYSTEINE PROTEASE POUR LE TRAITEMENT DE MALADIES ALLERGIQUES INDUITES PAR L'IMMUNOGLOBULINE E (IgE) |
US5780300A (en) | 1995-09-29 | 1998-07-14 | Yale University | Manipulation of non-terminally differentiated cells using the notch pathway |
AU706262B2 (en) * | 1995-10-23 | 1999-06-10 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
ATE254472T1 (de) | 1996-03-25 | 2003-12-15 | Chemo Sero Therapeut Res Inst | Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält |
US5945365A (en) | 1996-05-20 | 1999-08-31 | Fina Technology, Inc. | Stereorigid bis-fluorenyl metallocenes |
FR2754818B1 (fr) | 1996-10-23 | 1999-03-05 | Cird Galderma | Nouveaux derives bi-aromatiques du dibenzofuranne et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique |
US6077669A (en) | 1997-11-04 | 2000-06-20 | Becton Dickinson And Company | Kit and method for fluorescence based detection assay |
US5943585A (en) | 1997-12-19 | 1999-08-24 | Advanced Micro Devices, Inc. | Trench isolation structure having low K dielectric spacers arranged upon an oxide liner incorporated with nitrogen |
-
1997
- 1997-06-20 PL PL97330814A patent/PL330814A1/xx unknown
- 1997-06-20 CN CN97196755A patent/CN1226245A/zh active Pending
- 1997-06-20 IL IL12755997A patent/IL127559A0/xx unknown
- 1997-06-20 KR KR1019980710438A patent/KR20000022040A/ko not_active Application Discontinuation
- 1997-06-20 BR BR9711805-2A patent/BR9711805A/pt not_active Application Discontinuation
- 1997-06-20 CA CA002258822A patent/CA2258822A1/fr not_active Abandoned
- 1997-06-20 HU HU9904567A patent/HUP9904567A3/hu unknown
- 1997-06-20 EP EP97934849A patent/EP0912549A4/fr not_active Withdrawn
- 1997-06-20 WO PCT/US1997/010643 patent/WO1997048694A1/fr not_active Application Discontinuation
- 1997-06-20 AU AU37917/97A patent/AU727708B2/en not_active Ceased
- 1997-06-20 JP JP10503338A patent/JP2000514048A/ja active Pending
-
1998
- 1998-12-18 NO NO985975A patent/NO985975L/no not_active Application Discontinuation
-
2002
- 2002-03-27 US US10/108,606 patent/US6720344B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HUP9904567A2 (hu) | 2000-05-28 |
KR20000022040A (ko) | 2000-04-25 |
NO985975D0 (no) | 1998-12-18 |
WO1997048694A1 (fr) | 1997-12-24 |
HUP9904567A3 (en) | 2001-10-29 |
EP0912549A4 (fr) | 2002-01-02 |
CN1226245A (zh) | 1999-08-18 |
PL330814A1 (en) | 1999-06-07 |
BR9711805A (pt) | 2002-01-15 |
AU3791797A (en) | 1998-01-07 |
JP2000514048A (ja) | 2000-10-24 |
NO985975L (no) | 1999-02-18 |
EP0912549A1 (fr) | 1999-05-06 |
CA2258822A1 (fr) | 1997-12-24 |
US6720344B2 (en) | 2004-04-13 |
US20030119791A1 (en) | 2003-06-26 |
AU727708B2 (en) | 2000-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL127559A0 (en) | Compounds and methods for providing pharmacologically active preparations and uses thereof | |
HUP9904101A3 (en) | Solid foamed active substance preparations | |
AU4477597A (en) | New pharmaceutically active compounds | |
EP1017980A4 (fr) | Procede d'identification de composes pharmaceutiquement actifs | |
AU4143397A (en) | New pharmaceutically active compounds | |
AU5531798A (en) | Pharmacologically active compounds and use | |
GB9603431D0 (en) | Immunodulating active substance | |
AU4143297A (en) | New pharmaceutically active compounds | |
GB9616477D0 (en) | Pharmaceutically active compounds | |
GB9610474D0 (en) | Pharmaceutically active compounds | |
GB9610892D0 (en) | Pharmaceutically active compounds | |
GB9614385D0 (en) | Pharmaceutically active compounds | |
GB9614386D0 (en) | Pharmaceutically active compounds | |
GB9618487D0 (en) | Pharmaceutically active compounds | |
GB9610499D0 (en) | Pharmaceutically active compounds | |
GB9619122D0 (en) | Pharmaceutically active compounds | |
GB9602173D0 (en) | Pharmaceutically active compounds | |
GB9602667D0 (en) | Pharmaceutically active compounds | |
GB9602668D0 (en) | Pharmaceutically active compounds | |
GB9607717D0 (en) | Pharmaceutically active comounds | |
GB9721036D0 (en) | Spasminogenic preparations:methods and materials relating thereto | |
GB9609716D0 (en) | Pharmaceutically active compositions | |
GB9411998D0 (en) | Pharmaceutically active compounds | |
GB9409461D0 (en) | Pharmaceutically active compounds | |
GB9400920D0 (en) | Pharmaceutically active compounds |